Spoken Alpha
ZTS
Zoetis Inc.
Overview
Zoetis Inc is a Healthcare company operating in Drug Manufacturers - Specialty & Generic with a $32.35B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-0711 Q&A exchanges
- Q4 FY2025Earnings2026-02-1215 Q&A exchanges
- Q3 FY2025Earnings2025-11-049 Q&A exchanges
- Q2 FY2025Earnings2025-08-0510 Q&A exchanges
- Q1 FY2025Earnings2025-05-0610 Q&A exchanges
- Q4 FY2024Earnings2025-02-1310 Q&A exchanges
- Q3 FY2024Earnings2024-11-0410 Q&A exchanges
- Q2 FY2024Earnings2024-08-0611 Q&A exchanges
- Q1 FY2024Earnings2024-05-0211 Q&A exchanges
- Q4 FY2023Earnings2024-02-1410 Q&A exchanges
- Q3 FY2023Earnings2023-11-0210 Q&A exchanges
- Q2 FY2023Earnings2023-08-089 Q&A exchanges
- Q1 FY2023Earnings2023-05-0410 Q&A exchanges
- Q4 FY2022Earnings2023-02-1410 Q&A exchanges
- Q3 FY2022Earnings2022-11-0313 Q&A exchanges
- Q2 FY2022Earnings2022-08-049 Q&A exchanges
- Q1 FY2022Earnings2022-05-0510 Q&A exchanges
- Q4 FY2021Earnings2022-02-1511 Q&A exchanges
- Q3 FY2021Earnings2021-11-0412 Q&A exchanges
- Q2 FY2021Earnings2021-08-0512 Q&A exchanges
- Q1 FY2021Earnings2021-05-0616 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-03EPS— vs $1.85—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-03 | — | $1.85 | — | — | — | — | EODHD |
Source: EODHD. ZTS reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks ZTS's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $1.44 | $1.33 | +8.4% | -2.3% | -2.4% |
| Q4 FY2026 | $1.49 | $1.30 | +14.6% | -5.5% | -8.3% |
| Q3 FY2026 | $1.54 | $1.31 | +17.4% | +0.5% | -0.1% |
| Q2 FY2026 | $1.42 | $1.30 | +8.9% | +0.1% | -2.9% |
| Q1 FY2025 | $1.60 | $1.47 | +8.6% | -2.4% | -3.5% |
| Q4 FY2025 | $1.59 | $1.35 | +18.1% | -6.4% | -5.3% |
| Q3 FY2025 | $1.68 | $1.45 | +15.9% | +0.9% | -1.0% |
| Q2 FY2025 | $1.76 | $1.48 | +19.0% | -4.4% | -7.1% |
| Q1 FY2024 | $1.77 | $1.57 | +12.9% | -2.3% | +0.4% |
| Q4 FY2024 | $1.70 | $1.59 | +7.0% | +2.3% | +4.9% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Kristin C PeckCEO4 mo21 callsCurrentSample
CEO since 2026 • 2/2 beats (100%) • last guidance cut Q1 FY2026
- Wetteny JosephCFO4 mo20 callsCurrentSample
CFO since 2026 • 2/2 beats (100%) • guidance suspended Q2 FY2026
- Kevin EschExecutive Vice President4 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • guidance suspended Q3 FY2026
- Julie FullerExecutive Vice President4 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • last guidance raise Q1 FY2026
- Roxanne LaganoExecutive Vice President4 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • last call held guidance Q2 FY2026
- Astorga Jeannette FerranExecutive Vice President4 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • last guidance cut Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ZTS.
$ curl https://api.spokenalpha.com/v1/companies/ZTSFAQ
Frequently asked about ZTS
Where can I find Zoetis Inc.'s (ZTS) earnings call transcripts?
Spoken Alpha indexes ZTS's earnings call transcripts at https://spokenalpha.com/companies/ZTS. Each call links to attributed speakers and parsed analyst Q&A. Zoetis Inc.'s own investor relations page is at https://investor.zoetis.com/home/default.aspx.
When was Zoetis Inc.'s most recent earnings call?
Zoetis Inc. (ZTS) held its most recent earnings call on 2026-05-07, covering fiscal Q1 2026.
What sector is ZTS in?
Zoetis Inc. (ZTS) operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic industry).